ribaoo Research Daily

Primary papers first · explicit date boundaries · study-design-aware claims

28 July 2026 3D Bioprinting | latest visible batch
No. 2026-07-28 · latest-visible observation

LATEST VISIBLE BATCH

3D bioprinting of functional meniscus constructs with anisotropic properties using meniscus-derived bioink for knee meniscus regeneration.

Observation date: 2026-07-28. The primary-source endpoint did not yield a verifiable new batch in this run; this issue uses the latest visible record from 2026-07-24, not a publication-date claim for the observation date. The bioprinting screen covered bioprinting, 3D bioprinting, biofabrication, bioink, bioprinted tissue, in situ bioprinting, and linked additive manufacturing, excluding inert implants, dental models, surgical guides and teaching models unless living cells, bioink, tissue engineering or regenerative medicine were explicit.

Meniscal injuries frequently result in progressive degeneration of the knee joint, primarily due to the tissue's limited intrinsic healing capacity. To address this clinical challenge, we developed an anisotropic meniscus scaffold using three-dimensional (3D) bioprinting technology to promote functional regeneration. In this study, the scaffold was fabricated via 3D bioprinting, employing a composite of polyurethane and polycaprolactone polymers, meniscus derived decellularized extracellular matrix bioink, and mesenchymal stem cells (MSCs).In vitro, the bioprinted constructs, incorporating tissue-derived bioinks with region-specific stiffness, facilitated the differentiation of MSCs and extracellular matrix deposition in a manner that recapitulated the native anisotropic architecture of the meniscus.In vivo, the constructs demonstrated excellent chondroprotective effects and supported neo-meniscus formation in a canine model at 12 and 24 weeks post-implantation. These findings suggest that the engineered 3D bioprinted meniscus scaffold holds strong potential for clinical application in meniscal repair and regeneration.

Evidence boundary: 体外与犬模型证据,不是人体临床疗效;因活细胞、生物墨水和组织工程目标而入选。

Observation

2026-07-28

Asia/Shanghai

Latest visible source

2026-07-24

not a 28 July publication claim

Selected

1

primary-source and boundary screen

Same-day batch

unverified

a failed endpoint is not a zero-result claim